Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.59 |
| ▸ | BRAF | P15056 | 11/20 | 0.54 |
| ▸ | CSF1R | P07333 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943016 | 0.92 | PIKFYVE (0.70) | PIKFYVEBRAFCSF1RKITKDR | |
| SCHEMBL21943439 | 0.87 | PIKFYVE (0.56) | PIKFYVEBRAFKITKDRMAPK14 | |
| SCHEMBL21943518 | 0.87 | PIKFYVE (0.64) | PIKFYVEBRAFCSF1RPOLBKIT | |
| SCHEMBL21943068 | 0.85 | PIKFYVE (0.54) | PIKFYVEBRAFKDRMAPK14TNNI3K | |
| SCHEMBL21943657 | 0.85 | BRAF (0.53) | PIKFYVEBRAFCSF1RPOLBGAA | |
| SCHEMBL21943684 | 0.84 | KDR (0.51) | PIKFYVEBRAFCSF1RPOLBKIT | |
| SCHEMBL21943533 | 0.83 | KDR (0.58) | PIKFYVEBRAFCSF1RPOLBKIT | |
| SCHEMBL22024864 | 0.82 | PIKFYVE (0.85) | PIKFYVEBRAFCSF1RPOLBKIT | |
| SCHEMBL21944047 | 0.79 | PIKFYVE (0.67) | PIKFYVEBRAFCSF1RKDRMAPK14 | |
| SCHEMBL22024705 | 0.78 | PIKFYVE (0.75) | PIKFYVEBRAFCSF1RPOLBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | XIAMEN UNIVERSITY (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP4A11, CYP2D6, CYP3A43 | PIKFYVE 2706/4885BRAF 95/4885CSF1R 3749/4885 |
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | CYP4A11, CYP2D6, CYP3A43 | PIKFYVE 2706/4885BRAF 95/4885CSF1R 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.